Many researchers argue that this is inaccurate as they contend that the abfraction lesion is a multifactorial (has many causative factors) lesion with other factors such as abrasion or erosion. This controversy around the causative factors, along with the recency of the lesion classification, are some of the reasons why many dental clinicians are looking at the lesion with some scepticism. More research is needed to fully clear up the controversy surrounding the abfraction lesion. See also
Tooth wear
Abrasion
Attrition
Bruxism
Erosion

References

Summit, James B., J. William Robbins, and Richard S. Schwartz. Fundamentals of Operative Dentistry: A Contemporary Approach. 2nd edition. Carol Stream, Illinois, Quintessence Publishing Co, Inc, 2001. ISBN 0-86715-382-2. Lee, WC. ; Eakle, WS. (1984). "Possible role of tensile stress in the etiology of cervical erosive lesions of teeth". Journal of Prosthetic Dentistry. 52 (3): 374–380. doi:10.1016/0022-3913(84)90448-7. PMID 6592336.
No pharmaceutical companies were interested in selling the drug because hairy cell leukemia was an orphan disease, so Beutlers lab synthesised and packaged it and supplied it to the hospital pharmacy; the laboratory also developed a test to monitor blood levels. This was the first treatment that led to prolonged remission of hairy cell leukemia, which was previously untreatable. : 14–15 In February 1991, Scripps began a collaboration with Johnson & Johnson to bring intravenous cladribine to market, and by December of that year, Johnson & Johnson had filed a new drug application; cladribine was approved by the FDA in 1993 for hairy cell leukemia as an orphan drug, and was approved in Europe later that year. : 2 The subcutaneous formulation was developed in Switzerland in the early 1990s and it was commercialised by Lipomed GmbH in the 2000s. : 2

Safety profile of cladribine in hairy cell leukemia
Injectable cladribine suppresses the bodys ability to make new lymphocytes, natural killer cells, and neutrophils (called myelosuppression); data from hairy cell leukemia studies showed that about 70% of people taking the drug developed dangerously  low levels of white blood cells and about 30% developed infections and some of those progressed to septic shock; about 40% of people taking the drug had fewer red blood cells and became severely anaemic; and about 10% of people had too few platelets. At the dosage used to treat hairy cell leukemia in two clinical trials, 16% of people had rashes and 22% had nausea, the nausea generally did not lead to vomiting.